New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 4, 2012
09:12 EDTDTEGY, MTN, TEVA, BIG, S, PBY, GALE, PCS, ESIO, TOL, DRIOn The Fly: Pre-market Movers
HIGHER AFTER EARNINGS: Big Lots (BIG), up 7.3%... Toll Brothers (TOL), up 4.6%... ALSO HIGHER: Galena Biopharma (GALE), up 15% after signing NeuVax commercialization partnership with Teva (TEVA)... Electro Scientific (ESIO), up 12% after declaring $2/share special dividend... LOWER AFTER EARNINGS: Pep Boys (PBY), down 8.7%... Vail Resorts (MTN), down 7.3%... ALSO LOWER: Darden (DRI), down 8.9% after warning on Q2, FY13 EPS... MetroPCS (PCS), down 6.6% after Reuters says Sprint (S) unlikely to counter T-Mobile's (DTEGY) bid.
News For DRI;BIG;TOL;GALE;TEVA;ESIO;PBY;MTN;PCS;S;DTEGY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
April 16, 2015
15:40 EDTTEVAGeneric Copaxone approval a bit early but expected, says BMO Capital
BMO Capital believes FDA approval for Sandoz (NVS) and Momenta's (MNTA) generic 20mg Copaxone came slightly earlier than the market expected, but the firm added that the generic threat has been well expected. The firm added that it appears Mylanís (MYL) generic Copaxone hasn't been approved yet, leaving a "legitimate question" about why the FDA approved one generic and not the other. BMO thinks Teva's rate of conversion to the 40mg dose will help retain patients on the Copaxone franchise and it keeps an Outperform rating on Teva shares.
13:42 EDTTEVATeva shares defended at Evercore ISI
Subscribe for More Information
12:37 EDTTEVAMomenta confirms Glatopa approval, to receive $10M payment
Subscribe for More Information
12:35 EDTTEVASandoz receives FDA approval for Glatopa as generic competitor to Copaxone
Sandoz, a Novartis (NVS) company, announced the U.S. approval of Glatopa, the first generic version of Teva's (TEVA) Copaxone 20 mg/ml one-time-daily multiple sclerosis therapy. Glatopa, developed in collaboration with Momenta (MNTA) and produced entirely in the U.S., is indicated for the treatment of patients with relapsing forms of MS, including those who have experienced a first clinical episode and have magnetic resonance imaging features consistent with MS.
12:35 EDTTEVAFDA denies Teva attempt to block generic Copaxone
Subscribe for More Information
10:00 EDTDRIOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:16 EDTTEVAFormer Teva CEO appointed to position of CEO at Ovid Therapeutics
Ovid Therapeutics, a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, appointed Dr. Jeremy Levin as CEO. Levin has served as Chairman of Ovid since 2014 and will continue to serve in this role. Most recently, Levin served as CEO of Teva.
April 15, 2015
19:34 EDTTEVAVIVUS files patent infringement lawsuit against Teva
Subscribe for More Information
17:24 EDTDRIDarden initiated with a Neutral at Guggenheim
Subscribe for More Information
08:46 EDTPBYSynchrony Financial, Pep Boys extend consumer financing program
Subscribe for More Information
April 14, 2015
10:51 EDTSGoogle to sell mobile phone plans directly to customers, The Information reports
Google (GOOG) is looking to sell mobile phone plans directly to customers while managing their calls and mobile data over a cellular network, reports The Information. According to people with knowledge of the plans, the new service is expected to run on Sprint (S) and T-Mobile (TMUS) networks. Google expected to reach deals to buy wholesale across to those carriers' networks. A launch this year seems likely. Reference Link
10:16 EDTBIGHigh option volume stocks
High option volume stocks: NSAM ALU CJES BIG CMRX ERIC NTAP TMO KN CIG
10:01 EDTDRIDarden's Olive Garden unit enters into agreement with Ziosk for tabletop tablets
Olive Garden announced it has entered into an agreement with Ziosk, makers of ordering, entertainment and pay-at-the-table tablets, to begin the introduction of tabletop tablets in all of its restaurants nationwide. Olive Garden has been testing Ziosk in a select number of its restaurants since last year, and the feedback from guests and servers has been positive. Starting in May, Olive Garden will begin a phased rollout of Ziosk tablets into additional restaurants. The program will be supported by robust in-restaurant training to ensure this implementation reaches its full potential of enhancing the overall experience for guests and team members. Olive Garden expects Ziosk tablets to be in all of its 800-plus U.S. locations before the end of the calendar year.
08:03 EDTTEVATeva, Eagle announce NDA for bendamustine HCI accepted for filing
Subscribe for More Information
07:26 EDTGALEGalena completes over-enrollment of NeuVax Phase 3 PRESENT clinical trial
Galena Biopharma announced the completion of enrollment in the NeuVax Phase 3 PRESENT, or Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment, clinical trial. NeuVax is a first-in-class, HER2-directed cancer immunotherapy under evaluation to prevent breast cancer recurrence after standard of care treatment in the adjuvant setting. As anticipated, Galena over-enrolled the trial by 7.7% with a total of 758 patients now in the intent-to-treat, or ITT, population. The protocol for the PRESENT trial, being conducted under an FDA approved Special Protocol Assessment, or SPA, called for 700 patients; and, the company expects this higher number of ITT patients will increase the confidence in both the timing and quality of the statistics and the final outcome of the trial. The primary endpoint is currently expected to be reached in 2018, after the last patient dosed reaches her 36th month of treatment, or a total of 141 events occur, whichever comes later.
April 13, 2015
16:36 EDTPBYPep Boys CEO says seeing turn around in business
Subscribe for More Information
16:35 EDTPBYPep Boys reports Q4 EPS (50c) with items, consensus 3c
Subscribe for More Information
15:38 EDTPBYNotable companies reporting after market close
Subscribe for More Information
07:56 EDTTEVAMylan, Teva, Perrigo price targets raised at JPMorgan
Subscribe for More Information
06:06 EDTSSprint introduces Sprint Direct 2 U service
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use